Category Archives: Cardiomyopathies

BOSTON, May 4, 2020 /PRNewswire/ --Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens. Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. Prior to the live call, the webcast and dial-in information can be accessed by visiting the Investors & News section of Stealth's Investor website at https://investor.stealthbt.com/. Continue reading →

BOSTON, April 1, 2020 /PRNewswire/ --Stealth Biotherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2019 and announced recent business highlights. Continue reading →

BOSTON, March 30, 2020 /PRNewswire/ --Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report full year 2019 financial results on Wednesday, April 1, 2020, before the market opens. Stealth BioTherapeutics Logo (PRNewsFoto/Stealth BioTherapeutics) (PRNewsfoto/Stealth BioTherapeutics) Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. The call can be accessed by dialing (877) 407-0989 or (201) 389-0921 (international) and referencing conference ID 13701108. Continue reading →

Chandigarh, March 15 Heart patients dont need to panic over Covid-19. Continue reading →

Global Cell Culture Protein Surface Coating Market: Snapshot The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions Continue reading →

BOSTON, Feb. 27, 2020 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the 40th Annual Cowen Health Care Conference in Boston, MA on Wednesday, March 4 at 10:40 am ET. A live audio webcast of the event will be available on the Investors & News section of Stealth's website athttps://investor.stealthbt.com/ Continue reading →

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future. Continue reading →

SOUTH SAN FRANCISCO, Calif., Feb. Continue reading →

Too much exercise can cause atrial fibrillation Large observational studies have shown that a sedentary lifestyle increases the risk of atrial fibrillation fivefold.1,2 However, high-intensity aerobic exercise, especially for men, also increases the risk of atrial fibrillation at a threshold of more than 15002000 lifetime hours.3 Evidence is less clear for women.3 In the majority of athletes, atrial fibrillation is paroxysmal and symptomatic.2,3 High-intensity aerobic exercise causes increased hemodynamic stress and generates free radicals.4 The atria appear to be particularly susceptible, with resultant dilatation, chronic inflammation and fibrosis.24 Autonomic modulation also plays a role, and athletes commonly describe triggers that are vagally (sleep, meals) or adrenergically (exercise) mediated.2,3 It is important not to miss conditions associated with atrial fibrillation, including cardiomyopathies, channelopathies, pre-excitation, hyperthyroidism and alcohol or drug misuse.2,3 Energy supplements and performance enhancers should also be considered.2,3 Data on stroke risk among athletes are limited, but the use of thromboembolic risk scores (CHADS-65) is recommended.2,3,5 In nonrandomized studies, detraining has been shown to reduce atrial fibrillation, although athletes are often not willing to do this.2 Anti-arrhythmic medications are limited by bradycardia, impaired performance, long-term adverse effects and risk of ventricular arrhythmias during exercise.2,3 High-impact sports are a contraindication to anticoagulation.2,3 Data remain limited to small, nonrandomized studies, but ablation is often the preferred option for symptomatic athletes.2,3 Despite the distinct pathophysiology between symptomatic athletes and nonathletes, success rates appear similar to those of nonathletes: about 60% for the first procedure and > 80% for the second.2,3 Athletes not meeting CHADS-65 criteria must be informed of the need for anticoagulation for at least 2 months owing to the prothrombotic effect of catheter ablation.2,5 Continue reading →

That animal cohort underwent a procedure to permanently close off a specific portion of the coronary artery, called ligation, while another four rats were imaged with the same radiotracer, but did not undergo the surgery. Continue reading →